{"name": "Anadys",
 "permalink": "anadys",
 "crunchbase_url": "http://www.crunchbase.com/company/anadys",
 "homepage_url": "http://www.anadyspharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "",
 "description": "Biopharmaceutical Company",
 "created_at": "Tue Jun 16 23:58:49 UTC 2009",
 "updated_at": "Wed Jun 17 00:06:32 UTC 2009",
 "overview": "\u003Cp\u003EAnadys Pharmaceuticals is a biopharmaceutical company dedicated to developing medicines for the treatment of hepatitis C. The company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       50],
      "assets/images/resized/0004/8949/48949v1-max-150x150.png"],
     [[220,
       74],
      "assets/images/resized/0004/8949/48949v1-max-250x250.png"],
     [[220,
       74],
      "assets/images/resized/0004/8949/48949v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": true,
    "title": "Senior Manager, Corporate Development",
    "person":
     {"first_name": "Mark",
      "last_name": "Mahmood",
      "permalink": "mark-mahmood",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/6872/266872v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6872/266872v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/6872/266872v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$17.5M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/anadys-slashes-staff-finds-17-5m-hep-c-program/2009-06-04?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0",
    "source_description": "Anadys cuts staff, finds $17.5M for hep C program",
    "raised_amount": 17500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 6,
    "funded_day": 4,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "Corporate Headquarters",
    "address1": "3115 Merryfield Row",
    "address2": "",
    "zip_code": "92121",
    "city": "San Diego",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": 32.901186,
    "longitude": -117.238544}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}